KYTHERA is a privately-held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. The aesthetic market is characterized by an aging population, increasing discretionary income and an evolution of patient preference towards care that focuses on quality of life.

KYTHERA’s lead clinical program, ATX-101, is focused on the reduction of submental (‘under the chin’) fat. The company also has active research programs with focused interest in hair and fat biology, pigmentation modulation and facial contouring.